⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577198 | 0.71 | CYP1A2 (0.47) | — | |
| SCHEMBL565222 | 0.71 | CYP1A2 (0.47) | — | |
| SCHEMBL7571225 | 0.71 | CYP1A2 (0.47) | — | |
| SCHEMBL8629808 | 0.71 | — | — | |
| SCHEMBL151183 | 0.71 | CYP1A2 (0.47) | — | |
| SCHEMBL1069 | 0.71 | — | — | |
| SCHEMBL2474458 | 0.69 | — | — | |
| SCHEMBL633683 | 0.69 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL22679884 | 0.69 | — | — | |
| SCHEMBL4588662 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | claimed |
| EP-3137468-B1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2021-10-06 | — | — | EP | claimed |
| EP-3400209-B1 | ASCOCHLORIN DERIVATIVE AND USE THEREOF AS AMPK ACTIVATOR | HOSHINO TATSUO (JP) | 2021-09-22 | — | — | EP | claimed |
| EP-3318564-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-07-28 | — | — | EP | claimed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | claimed |
| EP-2629777-B1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-19 | — | — | EP | claimed |
| EP-3176170-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2018-11-14 | — | — | EP | claimed |
| EP-2986610-B9 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2018-10-17 | — | — | EP | claimed |
| EP-2692728-B1 | NOVEL FURANONE DERIVATIVE | CARNA BIOSCIENCES INC (JP) | 2018-07-04 | — | — | EP | claimed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| EP-1005445-B1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | claimed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | claimed |
| EP-0880508-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2003-04-16 | — | — | EP | claimed |
| EP-0815124-B1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2002-12-04 | — | — | EP | claimed |
| EP-0880517-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-01-16 | — | — | EP | claimed |
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | claimed |
| EP-0813519-B1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2001-05-09 | — | — | EP | claimed |
| EP-0636142-B1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LTD (GB) | 1998-06-17 | — | — | EP | claimed |
| EP-0647228-B1 | ASYMMETRIC HYDROGENATION OF FUROIMIDAZOLE DERIVATIVES | LONZA AG (CH) | 1996-06-26 | — | — | EP | claimed |
| EP-0171217-B1 | FUSED-RING HETEROCYCLIC COMPOUNDS A PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SANKYO COMPANY LIMITED (JP) | 1989-05-03 | — | — | EP | claimed |